China
I-Mab Announces Upcoming Participation at September Conferences
I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023.
Grit Biotechnology Announces Closing of $60 Million Series B Financing
On September 8, 2023, Grit Biotechnology announced the completion of a Series B financing round, raising over 60 million USD.
General Administration of Customs: The total value of imports and exports in the first eight months of this year was 8.27 trillion yuan, a slight decrease of 08.0%
According to the website of the General Administration of Customs on September 9, according to customs statistics, in the first eight months of this year, the total value of China's imports and exports was 7.8 trillion yuan, a slight decrease of 27.08% year-on-year.
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.
China’s big cities promise incentives to retain foreign research centres, talent as ‘uninvestable’ spectre haunts outlook
As fears grow that the flow of foreign cash and talent into the world’s second-largest economy may slow to a trickle, two major Chinese cities have launched charm offensives to retain foreign R&D centres.
BlackRock Pulls Back From China Under Intense Pressure
BlackRock is closing its China Flexible Equity fund as of November 7, 2023, the firm announced in an August 31 shareholder letter.
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha (PEG-IFNα) in patients with chronic hepatitis B (CHB) compared with PEG-IFNα only treatment.
First Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge’s team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD
Recently, NyokAssist™ was first-in-man (FIM) use, supporting High-risk PCI completed by Dr. Junbo Ge's team from Zhongshan Hospital in Shanghai.
Baird Medical’s Single-Use Sterile Biopsy Needle Receives Approval from Jiangsu Medical Products Administration in China
Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced that its subsidiary, Nanjing Changcheng Medical Equipment Co., Ltd., has received approval of its Single-Use Sterile Biopsy Needle ("SSBN") from Jiangsu Medical Products Administration, the drug regulatory body for Jiangsu Province in China.
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and commercialization of biologics in immuno-oncology, today announced that its fully human anti-PD-1 monoclonal antibody, Zimberelimab injection (YuTuo®, GLS-010) has received marketing approval from the China National Medical Products Administration (NMPA)
